Once again Bionaturis Group takes part in the Small and Medium-Sized Companies Forum (MedCap), organized by BME and hold in the Palacio de la Bolsa in Madrid from May 30th to June 1st. The biotechnological group will showcase the milestones achieved lately such as the YoY growth on net sales and revenues – +24.9% on sales and +1.4 million Euros on consolidated revenues- and the steady growth in license agreements signed –especially relevant for value capture on B2B business models -. Thus, achieved milestones like the Evaluation and Option agreement to register and commercialize worldwide the Bionaturis´ visceral canine leishmaniasis vaccine –BNT005- or the recent license contract with Biotandil to register, manufacture and market the same vaccine, in this case limited to Argentina and Paraguay, will be presented during the Forum.

Within the relevant license agreements side, special attention will also have the worldwide exclusive license agreement of Splittera to a multinational company for the industrial purification of biological products and the Extension of the Evaluation and Option License Agreement of Zera Subunit Vaccines 2.0 with a leading multinational company to develop biological vaccines for animal health.

The group will also point out the latest on its animal health portfolio such us the inclusion of Mupipet, a first in class medicine for pets for the prevention and treatment of bacterial infections on the skin of our beloved friends, among others.

Bionaturis Group CEO -Victor Infante- will present them all during the Discovery Meeting on May 31st at 9.30h, and the One to One pre-scheduled meetings as well. The full corporate presentation is available in the Relevant Information here.

About the MedCap Forum

The Medcap Forum is a major event and a must for European investors and listed medium/small-cap companies in Spain. The 13th Medcap Forum in 2017 will be held on May 30th and 31st and June 1st. The event will feature debate panels, private meetings and discovery meetings, networking activities between companies, investors and analysts and other financial personalities. The Medcap Forum encompasses the seventh MAB Encounter, where Alternative Securities Market (MAB) companies will be taking part in the panels, discovery meetings and other encounters.

To sum up: more than 100 listed companies, 150 investors, 800 in attendance and more than 1.200 private meetings between listed companies and buy-side investors.

For further information about the MedCap Forum, please, visit its website

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).